Explore ViiV Healthcare

I am a
... looking for

Medicines in Development

ViiV Healthcare is committed to developing new medicines for HIV to reduce its impact on the more than 1.1 million people in the US living with the virus.1 Our scientists and researchers continue to work to identify new ways to lessen the burden not only of the disease, but also of daily treatment of HIV.

Clinical development pipeline 

Product
Class
Phase
LA cabotegravir
INSTI
III
Combinectin (GSK3732394)
Entry inhibitor
Pre-clinical
GSK3640254
Maturation inhibitor
Pre-clinical
GSK3810109 Attachment inhibitor Pre-clinical

INSTI = integrase strand transfer inhibitor; LA = long-acting

  1. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV Surveillance Supplemental Report 2019;24(No. 1). Table 7, page 47. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-1.pdf. Last accessed November 2019.



Website images are not intended to imply that the models pictured have HIV.